Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

42.98USD
26 Aug 2016
Change (% chg)

$0.14 (+0.33%)
Prev Close
$42.84
Open
$42.87
Day's High
$43.28
Day's Low
$42.09
Volume
4,738,013
Avg. Vol
2,730,243
52-wk High
$46.62
52-wk Low
$36.00

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories plan slammed - CHITRI
Wednesday, 2 Mar 2016 08:15am EST 

Abbott Laboratories:Corporate layoffs are so routine that they usually don't attract much attention among lawmakers in Washington, D.C. But Abbott Laboratories' recent move to outsource some information technology jobs has come under scrutiny from Sen. Dick Durbin - CHITRI.The Illinois Democrat is upset about reports that the health care company, based in north suburban Abbott Park, is replacing American workers with foreign workers. In a letter to CEO Miles White released Monday, the senator urged Abbott to cancel the layoffs.Abbott spokesman Scott Stoffel declined to comment on Durbin's criticism.The company hasn't publicly disclosed any layoffs in recent weeks. Durbin heard about the planned dismissals during a Senate Judiciary Committee hearing last week on the impact of temporary visa programs, including H-1B's, used to bring immigrants, mainly from India, for technology work.Durbin's letter said 180 Abbott employees were given 60 days' notice and told their last day will be April 22. People who lost their jobs also were told they would have to train their replacements, adding insult to injury, the letter said.Abbott awarded an outsourcing contract to Wipro, a large India-based IT services firm, according to Durbin. After they are trained, the foreign workers will do these jobs outside the United States, his letter said.  Full Article

Abbott Declares Quarterly Dividend
Friday, 19 Feb 2016 09:55am EST 

Abbott (:declared a quarterly common dividend of 26 cents per share.cash dividend is payable May 16, 2016, to shareholders of record at the close of business on April 15, 2016.  Full Article

Abbott Laboratories to acquire Alere for $5.8 bln
Monday, 1 Feb 2016 08:00am EST 

Abbott Laboratories:To acquire Alere, becoming leader in point of care testing and significantly advancing global diagnostics presence.Abbott will pay $56 per common share at a total expected equity value of $5.8 billion.Says transaction expected to be immediately accretive to abbott's ongoing earnings per share upon close.Combination is anticipated to result in annual pre-tax synergies approaching $500 million by 2019.Sees approximately 12-13 cents of accretion in 2017 and more than 20 cents in 2018 from deal.Under the terms of the agreement, Alere will become a subsidiary of Abbott.Transaction has been approved by the boards of directors of Alere and Abbott.Evercore is acting as financial advisor and Kirkland & ellis llp is serving as legal counsel to Abbott.JP Morgan is acting as financial advisor and cravath, swaine & Moore is serving as legal counsel to Alere.  Full Article

Abbott Laboratories gives FY 2016 EPS guidance
Thursday, 28 Jan 2016 07:31am EST 

Abbott Laboratories:Issues FY 2016 adjusted EPS guidance range of $2.10 to $2.20.Projected FY 2016 EPS under GAAP is $1.55 to $1.65.Excluding impact of foreign exchange and Venezuela, the midpoint of Abbott's 2016 adjusted EPS guidance range would reflect strong double-digit growth.  Full Article

Abbott Laboratories declares dividend
Friday, 11 Dec 2015 10:18am EST 

Abbott Laboratories:Raising quarterly dividend for 44th straight year.Increases quarterly dividend to $0.26 per share from $0.24 per share.  Full Article

Abbott Laboratories narrows FY 2015 EPS guidance
Wednesday, 21 Oct 2015 07:45am EDT 

Abbott Laboratories:Narrowed its FY 2015 adjusted EPS guidance range for continuing operations to $2.14 to $2.16.Projected FY 2015 EPS for continuing operations under GAAP is $1.59 to $1.61.  Full Article

PharMerica Corp to pay $9.25 mln over allegations of kickbacks from Abbott Laboratories -DOJ - Reuters
Tuesday, 6 Oct 2015 08:00pm EDT 

Abbott Laboratories:PharMerica Corp will pay $9.25 million "to resolve allegations that it solicited and received kickbacks" to promote Abbott Labs' psychiatric drug Depakote for nursing home patients, the Department of Justice said on Wednesday - Reuters.About $6.75 million of the settlement will go to the federal government and $2.5 million will be used to cover Medicaid claims from states that opt to join the settlement, the department said in a statement - Reuters.  Full Article

Abbott Laboratories declared quarterly common dividend
Thursday, 17 Sep 2015 09:00am EDT 

Abbott Laboratories:Says that it has declared a quarterly common dividend of 24 cents per share.The cash dividend is payable Nov. 15, 2015, to shareholders of record at the close of business on Oct. 15, 2015.  Full Article

Abbott Laboratories' Abbott Healthcare tangles with regulators over Indian cough syrup complaint - Reuters
Saturday, 12 Sep 2015 08:00pm EDT 

Abbott Laboratories:Abbott Healthcare is challenging an Indian state's accusation that a sample of the company's cough syrup contained excessive levels of codeine, the second multinational to question India's regulatory testing regime in recent months - Reuters.Whether the sample of Abbott's popular "Phensedyl" was a genuine product or a fake has not been established, but the suspect batch of 80,000 bottles has not been recalled - Reuters.Abbott Healthcare is a unit of U.S.-based Abbott Laboratories - Reuters.The excessive codeine, an opium derivative, would violate Indian drugs law - Reuters.  Full Article

Abbott Completes Acquisition of Tendyne Holdings, Inc
Wednesday, 2 Sep 2015 09:00am EDT 

Abbott:Completed its acquisition of Tendyne Holdings, Inc., private medical device company focused on developing minimally invasive mitral valve replacement therapies.Abbott acquired the equity of Tendyne that it did not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future payments tied to regulatory milestones.  Full Article

RPT-Whiplashed investors stay skittish about St. Jude

Aug 26 One day after a short seller claimed that St. Jude Medical Inc's heart implants are vulnerable to deadly cyber attacks, investors appear most concerned about whether the accusation will derail St. Jude's $24 billion planned deal for Abbott Labs to buy it.